Surviving crises
as filed8.2/10
Has it survived what it has been through?
No warning events in its filings since 2022.
weight 22% of this tense · 82nd percentile among 497 sector filers · read for itself
From the record
Radiopharm Theranostics Limited's filings since 2022 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Track record
as filed9.4/10
What has it actually done, year after year?
+252.2% a year over 3 filed years; profit years unseen.
weight 45% of this tense · 94th percentile among 323 sector filers · read for its customers
From the record
Radiopharm Theranostics Limited's 3 filed years say what it did: revenue went from $292 thousand in fiscal 2023 to $4 million in fiscal 2025, up 252.2% a year; it rose in 2 of 2 years; it never fell from a peak (its annual reports).
What it rests on
- revenue growth over the filed span252.2%top 1% of its family
- the share of years revenue rosetop 8% of its family
- the deepest fall from a revenue peak0.0%top 10% of its family
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Shareholder treatment
SI estimate5.8/10
How has it treated the people who own it?
SI estimate 5.8/10, confidence 20 of 100 (family median).
weight 33% of this tense · 50th percentile among 295 sector filers · read for its shareholders
SI estimate Inferred, not read as filed
- Why it is an estimate
- Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 295 members with one.
- What the record cannot read
- Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
- How it was reasoned
- family median, 295 readings behind it.
- Confidence
- 20 of 100
- What would change it
- Its next annual report on file with the inputs replaces this estimate with the filed reading.
From the record
SI estimate, not a filed reading: Radiopharm Theranostics Limited's shareholder treatment is put at 5.8 of 10 with a confidence of 20 of 100, because fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income, so the desk assumes the typical reading of its industry family, the median of 295 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.